1. Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

3. Introduction/Overview

4. Controlling Glycemia Reduces Microvascular Complications: DCCT

5. Prevalence Rates of CV Comorbidities in Persons With T2DM: Results of a Systematic Literature Review

6. LEADER: Primary Outcome Liraglutide vs Placebo

7. SUSTAIN-6 (Semaglutide): Primary Outcome Results

8. Albiglutide: Results From the HARMONY Outcomes Trial

9. GLP-1 RAs and Improved Cardiac Function

10. EMPA-REG Primary Outcome (3-Point MACE): CV Death, Nonfatal MI, or Nonfatal Stroke

11. EMPA-REG: Results for CV Death and HHF

12. CANVAS (SGLT2i): Cardiovascular Results

13. DECLARE TIMI-58 (Dapagliflozin): MACE Results

14. Pharmacologic Therapy for T2DM: ADA/EASD 2018 Recommendations

15. New Paradigm for Treating the Patient With Both T2DM and CVD

16. The Kidneys and SGLT2 Inhibitors

17. Potential Mechanisms for CV Benefit Associated With Empagliflozin

18. Glucose Reduction and GLP-1RAs: Results Form the LEAD Trials

19. Despite Proven Advantages, Use of Newer Glucose-Lowering Agents Remains Low

20. Cardiologists Prescribing Anti-Hyperglycemics?

21. Summary and Conclusions

22. Abbreviations

23. Abbreviations (cont)